Cybin Inc (CYBN)

[Devolution]

Is anyone else watching besides you and I?

[The Night Stalker]

watching

[The Night Stalker]

dip

[The Night Stalker]

https://www.stockscores.com/chart.asp?TickerSymbol=%20cybn&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[BubbaInSC]

PPS Needs To Stay Above 50 day MA = 2.49

To be technically bullish. Big volume on 8/30/21 was bullish.

If pps breaks below support of 2.49, then pps will likely retest recent low of 200 day MA = 1.68

which way it goes...noone knows

winna winna chicken dinna for those who pick right :)

Did you pick some up on last dip?

[The Night Stalker]

https://www.stockscores.com/chart.asp?TickerSymbol=%20cybn&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[The Night Stalker]

https://www.stockscores.com/chart.asp?TickerSymbol=%20cybn&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[BubbaInSC]

Nice Break Above 50 Day MA = 2.45

[A-Gee10]

Anyone know when Cybin will have their next earnings call? Or did i miss it already?

[Robodoc]

If the patents are well founded, and pan out. I hope we break your charting models. So far the battles are in your favor. Maybe we both win the war.

[Robodoc]

Looks to have found its base Bubba. Again, as you called it days earlier.
Your charting technique has been spot on.

[BubbaInSC]

Time To Buy???

RSI = 28.14 = oversold?

[Robodoc]

Thanks Bubba, It's good to have you here.

[BubbaInSC]

Am Bullish This Is Normal Trading Pattern

Had taken some off the table back in July.

Good time to pick some up on these kinds of dips

There is an outside chance to pick up some at ~$1.80

Honestly don't know if it will or not. This is a strange time of year for trading

PPS is not quite oversold tho....lol

and pps appears to have broken down below support of 50 day MA = $2.31

Just as you called it in July Bubba.

I hope you feel more bullish now.

[Robodoc]

Just as you called it in July Bubba.

I hope you feel more bullish now.

[BubbaInSC]

was overbought folks taking profits

[Porman]

What is with the constant drop in PPS since starting to trade on the NYSE?

[BubbaInSC]

awesome sauce!

[Renee]

CLXPF changed to CYBN. Moved to the NYSE AMEX from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[BubbaInSC]

Cybin_Announces_Overnight_Marketed_Public_Offering_of_Common_Shares_US_Excluded

IMO, not good way to raise money and exclude USA.

Would expect raising $$$ and dilution for this type of stock.

Explains the sell off today; in addition to being overbought.

7/27/21 https://www.businesswire.com/news/home/20210727006106/en/Cybin-Announces-Overnight-Marketed-Public-Offering-of-Common-Shares

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has launched an overnight marketed public offering of common shares in the capital of the Company (the “Shares”) at a price per Share and for aggregate gross proceeds to be determined in the context of the market (the “Offering”).

The definitive Offering terms will be confirmed at the time of pricing pursuant to the terms of an underwriting agreement to be entered into between the Company, Cantor Fitzgerald Canada Corporation (“Cantor”), Canaccord Genuity Corp. (“Canaccord”) and a syndicate of underwriters (collectively, with Cantor and Canaccord, the “Underwriters”), with Cantor and Canaccord acting as co-lead underwriters and Cantor acting as sole bookrunner. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The Offering is expected to close on or about August 3, 2021, or such other date as the Underwriters and the Company may agree, and completion of the Offering will be subject to market and other customary conditions, including approval of the Neo Exchange Inc. (the “NEO Exchange”).

The Company intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the Shares offered in the proposed Offering on the same terms and conditions (the “Over-Allotment Option”). The Over-Allotment Option may be exercised in whole or in part as determined by the Underwriters.

The Company intends to use the net proceeds from the Offering for general corporate and working capital purposes.

The Shares will be offered in each of the provinces of Canada, excluding Quebec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021 (the “Base Shelf Prospectus”). The Shares will not be offered or sold in the United States or to U.S. persons except pursuant to Rule 144A or in such other manner as to not require registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). Prior to forming an investment decision, prospective investors should read the Base Shelf Prospectus and the documents incorporated by reference therein, including any marketing materials, which are available on the Company’s SEDAR profile available at www.sedar.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities to be offered have not been, and will not be registered under the U.S. Securities Act or under any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

[BubbaInSC]

this is huge

I was wondering why the recent run up in pps in past month

[psyched]

Cybin Announces Conditional Listing Approval from NYSE American

Wow! This came a lot faster than expected.


https://www.businesswire.com/news/home/20210721006001/en/Cybin-Announces-Conditional-Listing-Approval-from-NYSE-American

[BubbaInSC]

It's About Direction of PPS

rsi = 80 = overbought

likely short term direction is down

I agree that clxpf is about industry momentum and hyped potential and patents.

I don't think this stock price is about the current revenue. I believe it's all about future potential and maybe patents.

[Robodoc]

I don't think this stock price is about the current revenue. I believe it's all about future potential and maybe patents.

[BubbaInSC]

RSI = 80 = overbought

time to sell a bit?

[Reyeton]

An interesting perspective, perhaps:

[Emerging Growth Conf]

Emerging Growth Conference Presenter $CLXPF +13% Today!

Registration link for the next Emerging Growth / Investors Hub Conference here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164827214

[BubbaInSC]

CLXPF On The Move Again

[Reyeton]

https://www.technologynetworks.com/neuroscience/news/psychedelic-compound-psilocybin-can-remodel-connections-in-the-brain-350530

[BubbaInSC]

California_advances_decriminalizing_psychedelic_substances


6/29/21
https://apnews.com/article/california-health-government-and-politics-c3eb439025f5f0b50090c73f22183cd0

SACRAMENTO, Calif. (AP) — California on Tuesday moved another step closer to decriminalizing psychedelics — amid a debate over whether their prohibition is an outdated remnant of the War on Drugs — after the author removed a substance from the bill that opponents said can be used as a date-rape drug.

The bill would allow those 21 and older to possess for personal use and “social sharing” psilocybin, the hallucinogenic component of so-called magic mushrooms. It also covers psilocyn, dimethyltryptamine (DMT), ibogaine, mescaline excluding peyote, lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA, often called ecstasy).

“People’s lives are literally transformed because of these substances,” said Sen. Scott Wiener, a Democrat from San Francisco, though he amended his bill to remove ketamine from the list.


Keeping the potential date-rape drug “would have just confused what you ultimately want to get accomplished,” said the Assembly Public Safety Committee’s chairman, Democratic Assemblyman Reggie Jones-Sawyer, who otherwise supported the bill.

Psychedelics have emerged as “an extremely promising approach to a variety of mental illnesses,” testified Dr. Robert Grant, who studies ketamine-assisted psychotherapy for depression and anxiety at the University of California, San Francisco, which is creating a research center in August to study their use. “Certainly people should not be incarcerated for seeking a healing path with these medications.”

The bill bars sharing with those under age 21 or possessing the substances on school grounds. It would remove the state’s ban on cultivating or transferring mushroom spores or other material containing psilocybin or psilocyn.

Even if California makes the bill law, the drugs would still be illegal under federal law.

It cleared the Assembly Public Safety Committee, 5-3, with proponents touting the benefits to military veterans and others they say can benefit from the use of psychedelics to treat trauma. The measure already passed the state Senate on a 21-16 vote and now heads to the health committee before it can go to the full Assembly.

“Having tried all that was offered to me by military medicine, I was barely holding on. I turned to psychedelics as a last-ditch effort to survive, and fortunately it worked amazingly well,” testified Jesse Gould, the founder and president of the Heroic Hearts Project who served three combat tours as an Army Ranger.

Oregon voters last year approved decriminalizing small amounts of psychedelics among other drugs, and separately were the first to approve the supervised use of psilocybin in a therapeutic setting.


Oakland and Santa Cruz are among cities including Washington, D.C.; Ann Arbor, Michigan; and Somerville and Cambridge, Massachusetts, that have decriminalized certain natural psychedelics that come from plants and fungi. Denver was the first U.S. city to decriminalize hallucinogenic mushrooms for personal use two years ago.

California Narcotics Officers Association legislative director John Lovell said the organization doesn’t seek to incarcerate anyone for drug use.

But he told the committee that the bill’s allowance of social sharing could bring more overdoses and fatalities from contaminated drugs, and LSD should be excluded because “it is married to flashbacks” and can result in “a trip people can have for the rest of their lives.”

Even with the removal of ketamine, “there are still many dangerous, illegal drugs” on the list that lack approval by the U.S. Food and Drug Administration, said Frank Lee, president of the Organization for Justice and Equality. Moreover, he said, allowing for social sharing is “effectively giving the drug dealers a built-in defense.”

Republican Assemblyman Kelly Seyarto said he favors anything that helps veterans, but “it has to be done in a clinical setting, it has to be done under the watchful eye of a physician” to make sure there are no ill effects.

Under Wiener’s bill, he said, “this will be just like beer, you just go get the 21-year-old to give you the stuff.”

Wiener cited studies by Johns Hopkins University, the University of California, San Francisco and UCLA that found psychedelic therapies can help where other treatments have failed. He said other research has shown the use of MDMA can help reduce the severity of post-traumatic stress disorder.

His bill would require the California Department of Public Health to create a working group to study the regulation and use of the drugs and make recommendations to lawmakers.

But his bill goes beyond allowing only therapeutic use. He argued the broader lifting of penalties is another step away from penalizing nonviolent drug offenses and what Wiener called the failed policies of the 50-year War on Drugs that have ”made us less safe because people use in the shadows.”

“It’s time we acknowledge the benefits of these substances even outside of a clinical study,” Wiener said. Opposition to legalizing the drugs “is like the psychedelic equivalent of ‘Reefer Madness,’ that this is going to do all sorts of horrible things. And that is just not true.”

Among other things, his bill would repeal provisions in state law saying that messages from state drug and alcohol programs should promote abstaining from the unlawful use of any drugs or alcohol.

[Emerging Growth Conf]

$CLXPF - Emerging Growth / Investors Hub Conference Replay available here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164694718

[Emerging Growth Conf]

$CLXPF Conference Replay now available.

Conference Replay and next conference registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164585602

[Reyeton]

Fasten your seat belts.

https://finance.yahoo.com/news/cybin-announces-former-fda-psychiatry-110000057.html

[Emerging Growth Conf]

$CLXPF Live on the The Emerging Growth / Investors Hub Conference in 30 minutes!

Registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164552663


Other Companies Presenting Today:
$RKV

Follow for Replay Notification
$NSAV & VirtuaBroker
$LQAVF / $LQID
$ERVFF / $EV
$FTXP
$GSVRF / $GSVR
$PHIL
$CBDD
$PBIO

[psyched]

Stifel GMP- CYBN $15 Price Target


https://stifel2.bluematrix.com/sellside/EmailDocViewer?encrypt=d598f42f-35c9-40a9-9629-215afac80329&mime=pdf&co=Stifel&id

[NewsWire [Tiffany] (former)]

Check out the Emerging Growth / InvestorsHub Conference Message Board as Cybin will be presenting on June 23rd at the conference.

Find more information and how to register here:
https://investorshub.advfn.com/Emerging-Growth-InvestorsHub-Virtual-Conference-39694/

[Emerging Growth Conf]

Cybin, Inc. (OTCQB: CLXPF) Presenting Live on Emerging Growth Conference 10 - June 23, 2021

Registration Link here:

https://goto.webcasts.com/starthere.jsp?ei=1473091&tp_key=f82736754c&sti=egihub

[BubbaInSC]

yep yep buy low sell high

[Mushyheaded]

Mmmm, let em sell. I'm buyin ;)

Thanks.

[Nosnibor]

Boring chartist. Zzzzzzzzz so naive.

[BubbaInSC]

Not_Sure_I'll_Take_A_Look_Over_Weekend

At a quick glance, pps broke resistance of 50 day MA on 4/26/21. New resistance is ~$1.80ish. The 50 day MA = $1.39 is new support.

Still appears bullish short term. PPS needs to stay above 50 day MA.
If it breaks below 50 day MA, you may be able to pick up some at $1.20

Only worry is "sell in May and go away".

The Market is fickle.....lol

[Nosnibor]

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Post published:May 20, 2021
Post category:Press Release

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new provisional patent application in support of its ongoing drug candidate programs.

The application discloses novel compositions which are expected to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules and discloses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybin’s psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof.

The patent application further reveals innovative methods directed to leveraging the disclosed compositions to promote decreased time to therapeutic onset, decreased duration of action, and decreased side effects.

Patent Filing Highlights:

The Company has a provisional patent application including disclosures directed to novel oral dosage forms believed to provide therapeutic advantages in addressing the Company’s target indications over the current art.
The patent application is synergistic with other patent applications filed by the Company related to a delivery technology covering various chemically synthesized psychedelic molecules which is expected to provide faster onset times in a similar route to intravenous treatments.
The patent application bolsters the Company’s portfolio related to deuterated psychedelic molecules and analogues which are expected to provide greater stability, better potency, more control over duration and greater bioavailability than other forms of these molecules.
The patent application disclosures related to faster therapeutic onset, decreased duration, and decreased side effects are anticipated to greatly reduce the clinical costs of administration resulting from reduced clinical observation time.

“By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” stated Doug Drysdale, Chief Executive Officer.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Company’s new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

[Mushyheaded]

Cybin Inc. released 12th patent: https://www.cybin.com/press-release/cybin-files-its-12th-patent-further-strengthening-ip-portfolio-of-novel-psychedelic-molecules-and-delivery-mechanisms

Bubba, you called it perfectly. Test levels at $1, resistance at 1.5.
I've swung it a couple times but I'd like to consolidate and go long.
Hmm. I'm assuming if I'm patient enough, I'll get another crack at $1--maybe 1.2ish?

[psyched]

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder




https://www.businesswire.com/news/home/20210518005402/en/Cybin-Granted-IRB-Approval-for-Phase-II-Clinical-Trials-of-its-Sublingual-Psilocybin-Formulation-for-the-Treatment-of-Major-Depressive-Disorder

[psyched]

Stifel GMP just upgraded their Spec Buy on Cybin and increased price target from $5 to $11 https://stifel2.bluematrix.com/sellside/EmailDocViewer?encrypt=2f363506-6a24-4676-a189-50620fc2dd7a&mime=PDF&co=Stifel&id

[BubbaInSC]

^This

NASDAQ listing of MNMD was a nice catalyst.

Am spreading some $$ with some different stocks in this niche

This along side MMED Nasdaq listing is great for the industry

[psyched]

Put Cybin Stock on Your Radar [url]https://www.fool.com/investing/2021/04/29/forget-sundial-growers-put-this-psychedelic-stock/

[Space Cats]

$CLXPF Much obliged. This looks good long term.

[psyched]

Just sharing this US$10 per share price target from Roth Capital on Cybin. This along side MMED Nasdaq listing is great for the industry https://drive.google.com/file/d/17ehc_3IKD9N4kmP5wnArwNkAyGYMUVId/view

[Nosnibor]

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Post published:April 26, 2021
Post category:Press Release

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003.

AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.1

Approximately 5.8 percent or 14.4 million adults in the United States ages 18 and older had AUD in 2018. This includes 9.2 million men and 5.3 million women.1 To be diagnosed with AUD, individuals must meet certain criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (“DSM”). Under DSM–5, the current version of the DSM, anyone meeting any two of the 11 criteria during the same 12-month period receives a diagnosis of AUD. The severity of AUD—mild, moderate, or severe—is based on the number of criteria met.1

“The evidence of increased alcohol use during this ongoing pandemic is startling. For so many individuals and families, Alcohol Use Disorder can be disruptive, even devastating. We are optimistic that CYB003 could have the potential to improve the lives of AUD sufferers and their loved ones by providing a durable respite from alcohol dependence and the potential to overcome this often-crippling disease,” stated Doug Drysdale, Chief Executive Officer.

Cybin is confident that its proprietary deuterated CYB003 New Chemical Entity (“NCE”) could be an ideal investigational new drug (“IND”) candidate for a future AUD clinical trial once further pre-clinical data has been collected. Cybin is targeting an IND filing for CYB003 by the end of calendar 2021.

Cybin’s intellectual property-driven strategy focuses on the discovery of NCEs derived from parent molecules with the potential to be faster acting and more commercially viable with an optimized duration of action, utilizing proprietary deuteration processes. As the psychedelic industry continues to evolve with positive studies, Cybin believes that these molecules may have the potential to fill current unmet treatment needs for various psychiatric and neurological conditions.

Alcohol-Related Emergencies and Deaths in the United States2

The rate of all alcohol-related ED visits increased 47 percent between 2006 and 2014.
Alcohol contributes to about 18.5 percent of ED visits and 22.1 percent of overdose deaths.
An estimated 95,000 people in the U.S. (approximately 68,000 men and 27,000 women) die from alcohol-related causes annually, making alcohol the third-leading preventable cause of death in the United States.
Between 2011 and 2015, the leading causes of alcohol-attributable deaths due to chronic conditions in the United States included alcohol-associated liver disease, heart disease and stroke, liver cirrhosis, digestive tract cancers, liver cancer, breast cancer, and hypertension.
In 2015, alcohol-impaired driving fatalities accounted for 29.0 percent of all driving fatalities.
In 2010, alcohol misuse cost the United States $249 billion. Three-quarters of the total cost of alcohol misuse is related to binge drinking.

Global Burden2

In 2016, 3 million deaths, or 5.3 percent of all global deaths were attributable to alcohol consumption.
Globally, alcohol misuse was the seventh-leading risk factor for premature death and disability in 2016.
According to a 2014 World Health Organization (“WHO”) report, alcohol misuse was the first-leading risk factor for premature death and disability, among people ages 15 to 49.
In 2016, 5.3 percent of the burden of disease and injury worldwide (134 million disability-adjusted life-years [“DALYs”]) was attributable to alcohol consumption.
In 2018, WHO reported that alcohol contributed to more than 200 diseases and injury-related health conditions, ranging from liver diseases, road injuries, and violence, to cancers, cardiovascular diseases, suicides, tuberculosis, and HIV/AIDS.

1 https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-use-disorder

2 https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics

About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.